8. Definitions and results of anti‐anti‐idiotypic (Ab3) humoral responses in antigen‐specific antibody studies.

Study	N	Dose	Target antigen	Analysed	Positive if:	% positive	Robust if:	% robust
Baumann 2011	45	C1: 10‐10‐10‐10 μg C2: 10‐20‐50‐100 μg	EpCAM	no
Berek 2001	252	2 mg	CA‐125	no
Berek 2004	145	2 mg	CA‐125	no
Berek 2009	371	2 mg	CA‐125	no
Braly 2009	40	unknown	CA‐125	no
Buzzonetti 2014	129	2 mg	CA‐125	yes; reported in Sabbatini 2013
Ehlen 2005	13	2 mg	CA‐125	yes	> 100 ng/mL		> 3× baseline	0%
Gordon 2004	20	2 mg	CA‐125	yes	> 100 ng/mL		> 3× baseline	10.5%
Heiss 2010	129	10‐20‐50‐150 μg	EpCAM	no
Ma 2002	4	unknown	CA‐125	no
Method 2002	102	2 mg	CA‐125	no
Möbus 2003	44	2 mg	CA‐125	yes			> 3× baseline	28%
Nicholson 2004	26	25 mg	MUC1	yes	> 0.015 μg/mL	38%
Noujaim 2001	184	2 mg	CA‐125	yes			> 3× baseline	43%
Pfisterer 2006	36	2 mg	CA‐125	yes	> 1000 ng/mL	L vs S: 100% vs 100%
Reinartz 2004	119	2 mg	CA‐125	yes	> 1000 μ/mL	68%
Sabbatini 2006	42	2 mg/0.2 mg	CA‐125	yes	> 1000 μ/mL	100%
Sabbatini 2013	888	2 mg	CA‐125	yes	unknown	placebo: stable abagovomab: increase
Schultes 1998	75	2 mg	CA‐125	yes	> 200 ng/mL	24%	> 3× baseline
Ströhlein 2009	2	10/20/40 μg 10/40/80 μg	EpCAM Her‐2/Neu	no
van Zanten‐Przybysz 2002	5	50 mg	membrane folate receptor	no
Wagner 1993	58	1 mg	CA‐125	no